Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bial

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44064   clinical trials with a EudraCT protocol, of which   7320   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Bial. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-004583-30 Sponsor Protocol Number: BIA-DPT-P2-001 Start Date*: 2012-01-16
    Sponsor Name:BIAL Industrial Farmaceutica
    Full Title: A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCT...
    Medical condition: Allergic rhinoconjunctivitis with or without associated asthma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001459-22 Sponsor Protocol Number: BIA-PAR-DEPOT Start Date*: 2015-02-20
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: OPEN CLINICAL TRIAL, MULTICENTER, WITH SUBCUTANEOUS IMMUNOTHERAPY IN DEPOT PRESENTATION, IN PATIENTS WITH ALLERGY RHINOCONJUNCTIVITIS SENSITIZED TO PARIETARIA JUDAICA
    Medical condition: PATIENTS WITH RHINOCONJUNCTIVITIS SENSITISED TO PARIETARIA JUDAICA
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019100-23 Sponsor Protocol Number: BIA-2093-307 Start Date*: 2010-12-02
    Sponsor Name:BIAL – PORTELA & Ca, S.A.
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain
    Medical condition: Diabetic Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004317-42 Sponsor Protocol Number: IT-OLE-LOL-DP Start Date*: 2005-02-25
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: Ensayo clínico aleatorizado, doble ciego, doble dummy, controlado con placebo, para valorar la eficacia y seguridad de diferentes presentaciones de inmunoterapia subcutánea en pacientes asmáticos s...
    Medical condition: Asma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019101-42 Sponsor Protocol Number: BIA-2093-308 Start Date*: 2010-07-21
    Sponsor Name:BIAL – PORTELA & Ca, S.A.
    Full Title: A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia
    Medical condition: Post-herpetic neuralgia (PHN).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-002754-24 Sponsor Protocol Number: BIA-91067-403 Start Date*: 2021-07-06
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the tre...
    Medical condition: Parkinson's Disease (PD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) PT (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002448-10 Sponsor Protocol Number: BIA-51058-201 Start Date*: 2018-10-31
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)
    Medical condition: Pulmonary arterial hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) PT (Completed) ES (Ongoing) GB (Temporarily Halted) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001072-29 Sponsor Protocol Number: BIA-2093-211/EXT Start Date*: 2017-06-29
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET S...
    Medical condition: refractory epilepsy with partial-onset seizures in children aged from 1 month to < 2 years
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10065336 Partial epilepsy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) IT (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-001243-36 Sponsor Protocol Number: BIA-2093-311/EXT Start Date*: 2015-11-06
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MU...
    Medical condition: Adult patients with recently diagnosed partial-onset seizures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) LT (Completed) CZ (Completed) LV (Completed) PT (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) EE (Completed) AT (Completed) BG (Completed) SK (Completed) FI (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002796-18 Sponsor Protocol Number: BIA-51058-202 Start Date*: 2019-07-30
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002391-27 Sponsor Protocol Number: BIA-OPC-401 Start Date*: 2016-10-07
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: This action will amend the information submitted in this data field for all relevant applications. Please refer to the guidance under the Amendment tab and consider whether further notification to...
    Medical condition: Parkinson's disease (PD) patients with wearing-off motor fluctuations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001176-15 Sponsor Protocol Number: BIA-91067-405 Start Date*: 2021-05-07
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders.
    Medical condition: Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000814-21 Sponsor Protocol Number: BIA-PHL-P2-001 Start Date*: 2011-09-02
    Sponsor Name:BIAL INDUSTRIAL FARMACEUTICA, S.A.
    Full Title: A phase II, multicentre, randomized, double-blind study with subcutaneous immunotherapy at different doses, in parallel groups and placebo controlled in patients with rhinoconjunctivitis ± asthma s...
    Medical condition: allergic rhinoconjunctivitis induced by grass pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002944-18 Sponsor Protocol Number: BIA-HDMP-201 Start Date*: 2016-11-14
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC R...
    Medical condition: The disease under study is allergic rhinoconjunctivitis secondary to sensitization to DPT and DF. Included in the study are patients diagnosed with that disease who also have associated mild asthma...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003137-41 Sponsor Protocol Number: BIA-2093-212 Start Date*: 2012-12-19
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: DOUBLE-BLIND STUDY IN PAEDIATRIC EPILEPTIC SUBJECTS AGED FROM 5 TO LESS THAN 8 YEARS TO COMPARE THE SUBJECT PREFERENCE FOR ESL SUSPENSION FORMULATION WITH ALTERNATIVE FLAVOURS
    Medical condition: Epilepsy / Partial onset seizures
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005011-52 Sponsor Protocol Number: BIA-91067-303 Start Date*: 2021-05-12
    Sponsor Name:BIAL – Portela & Cª, S.A.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase ...
    Medical condition: Early Idiopathic Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) PT (Completed) FR (Completed) BE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021860-13 Sponsor Protocol Number: BIA-91067-301 Start Date*: 2010-11-11
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMIS...
    Medical condition: Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) AT (Completed) LV (Completed) DE (Completed) ES (Completed) PT (Completed) CZ (Completed) SK (Completed) BG (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001091-11 Sponsor Protocol Number: BIA-2093-211 Start Date*: 2017-06-29
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET S...
    Medical condition: refractory epilepsy with partial-onset seizures in children aged from 1 month to < 2 years
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10065336 Partial epilepsy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) IT (Completed) HR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-012587-14 Sponsor Protocol Number: BIA-2093-401 Start Date*: 2010-01-14
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: SEGURIDAD Y EFICACIA DEL ACETATO DE ESLICARBAZEPINA (ESL) COMO TERAPIA ADYUVANTE PARA CRISIS PARCIALES EN PACIENTES MAYORES/ SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERA...
    Medical condition: Terapia adyuvante de crisis parciales en pacientes mayores / Adjunctive therapy of partial-onset seizures in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    12.0 10015037 Epilepsy PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) AT (Completed) PT (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-002131-27 Sponsor Protocol Number: SCO/BIA-2093-203 Start Date*: 2005-09-27
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: Efficacy and safety of eslicarbazepine acetate (BIA 2-093) in acute manic episodes associated with bipolar I disorder in a double-blind, randomised, dose-titration, placebo-controlled, multicenter ...
    Medical condition: Patients with acute manic episode fulfilling DSM-IV criteria for Bipolar I Disorder (i.e., 296.0, 296.4 or 296.6)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) CZ (Completed) DE (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Sep 20 03:23:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA